Global Intravenous (IV) Solution

Intravenous (IV) Solution Comprehensive Study by Type (Saline, Dextran, Lactated Ringers, Amino Acids), Application (Hospitals & Clinics, Ambulatory, Homecare), Nutrition Type (Carbohydrates, Salts and Electrolytes, Minerals, Vitamins, Amino Acids) Players and Region - Global Market Outlook to 2030

Intravenous (IV) Solution Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 11.5%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Intravenous (IV) Solution Market Scope
Intravenous (IV) solutions involve the direct administration of a liquid substance into a vein through a needle or catheter, facilitating the swift and direct delivery of fluids, medications, electrolytes, or nutrients into the bloodstream. Widely employed in medical settings like hospitals, clinics, and emergency care, IV solutions serve various purposes, including addressing dehydration, correcting electrolyte imbalances, and delivering medications requiring rapid absorption

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
Key Companies ProfiledBaxter International Inc.(United States), ICU Medical Inc. (United States), B. Braun Melsungen AG (Germany), Grifols, S.A. (Spain), Fresenius Kabi USA, LLC (United States), Vifor Pharma Management Ltd (Switzerland), JW Life Science (South Korea) and Amanta Healthcare (India)
CAGR11.5%


The major players are focusing on creating advanced intravenous products, such as the formulation of new solutions with improved efficiency, the integration of innovative technologies like smart infusion pumps, and the development of personalized therapies Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Intravenous (IV) Solution market throughout the predicted period.

Baxter International Inc.(United States), ICU Medical Inc. (United States), B. Braun Melsungen AG (Germany), Grifols, S.A. (Spain), Fresenius Kabi USA, LLC (United States), Vifor Pharma Management Ltd (Switzerland), JW Life Science (South Korea) and Amanta Healthcare (India) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Fresenius Kabi (Germany), Baxter (United States), Terumo Medical Corporation (Japan) and Grifols (Spain).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Intravenous (IV) Solution market by Type , by Application (Hospitals & Clinics, Ambulatory and Homecare) and Region with country level break-up.

On the basis of geography, the market of Intravenous (IV) Solution has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2023.

Market Leaders and their expansionary development strategies
In January 2022, ICU Medical Inc. announced that it has completed its acquisition of Smiths Medical from Smiths Group plc . The Smiths Medical business includes syringe and ambulatory infusion devices, vascular access, and vital care products. When combined with ICU Medical’s existing businesses, the combined companies create a leading infusion therapy company with estimated pro forma combined revenues
In June 2019, Eurolife Healthcare company launched the high quality Intravenous IV Products Disport and Lifeport in the Indian drug market positioned as smart intravenous infusion both product ecomposes best latest technology that reduce chance of any infection.


Influencing Trend:
A growing trend involves the administration of IV treatments in the comfort of patients' homes, enhancing convenience

Market Growth Drivers:
The Increasing of prevalence of chronic diseases is driving the intravenous solution

Challenges:
IV administration requires specialized equipment and trained personnel and Certain individuals may be allergic to components of IV solutions

Restraints:
There is a potential risk of developing blood clots at the injection site and High cost of IV Solutions

Opportunities:
Healthcare providers can precisely control fluid balance and electrolyte levels and IV solutions play a vital role in emergency situations, providing a quick response to critical medical needs

Key Target Audience
Supplier, Provider, Distributer and Others

Report Objectives / Segmentation Covered

By Type
  • Saline
  • Dextran
  • Lactated Ringers
  • Amino Acids
By Application
  • Hospitals & Clinics
  • Ambulatory
  • Homecare
By Nutrition Type
  • Carbohydrates
  • Salts and Electrolytes
  • Minerals
  • Vitamins
  • Amino Acids

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The Increasing of prevalence of chronic diseases is driving the intravenous solution
    • 3.3. Market Challenges
      • 3.3.1. IV administration requires specialized equipment and trained personnel
      • 3.3.2. Certain individuals may be allergic to components of IV solutions
    • 3.4. Market Trends
      • 3.4.1. A growing trend involves the administration of IV treatments in the comfort of patients' homes, enhancing convenience
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Intravenous (IV) Solution, by Type, Application, Nutrition Type and Region (value and volume ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Intravenous (IV) Solution (Value)
      • 5.2.1. Global Intravenous (IV) Solution by: Type (Value)
        • 5.2.1.1. Saline
        • 5.2.1.2. Dextran
        • 5.2.1.3. Lactated Ringers
        • 5.2.1.4. Amino Acids
      • 5.2.2. Global Intravenous (IV) Solution by: Application (Value)
        • 5.2.2.1. Hospitals & Clinics
        • 5.2.2.2. Ambulatory
        • 5.2.2.3. Homecare
      • 5.2.3. Global Intravenous (IV) Solution by: Nutrition Type (Value)
        • 5.2.3.1. Carbohydrates
        • 5.2.3.2. Salts and Electrolytes
        • 5.2.3.3. Minerals
        • 5.2.3.4. Vitamins
        • 5.2.3.5. Amino Acids
      • 5.2.4. Global Intravenous (IV) Solution Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Intravenous (IV) Solution (Volume)
      • 5.3.1. Global Intravenous (IV) Solution by: Type (Volume)
        • 5.3.1.1. Saline
        • 5.3.1.2. Dextran
        • 5.3.1.3. Lactated Ringers
        • 5.3.1.4. Amino Acids
      • 5.3.2. Global Intravenous (IV) Solution by: Application (Volume)
        • 5.3.2.1. Hospitals & Clinics
        • 5.3.2.2. Ambulatory
        • 5.3.2.3. Homecare
      • 5.3.3. Global Intravenous (IV) Solution by: Nutrition Type (Volume)
        • 5.3.3.1. Carbohydrates
        • 5.3.3.2. Salts and Electrolytes
        • 5.3.3.3. Minerals
        • 5.3.3.4. Vitamins
        • 5.3.3.5. Amino Acids
      • 5.3.4. Global Intravenous (IV) Solution Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
  • 6. Intravenous (IV) Solution: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Baxter International Inc.(United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. ICU Medical Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. B. Braun Melsungen AG (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Grifols, S.A. (Spain)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Fresenius Kabi USA, LLC (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Vifor Pharma Management Ltd (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. JW Life Science (South Korea)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Amanta Healthcare (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Intravenous (IV) Solution Sale, by Type, Application, Nutrition Type and Region (value and volume ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Intravenous (IV) Solution (Value)
      • 7.2.1. Global Intravenous (IV) Solution by: Type (Value)
        • 7.2.1.1. Saline
        • 7.2.1.2. Dextran
        • 7.2.1.3. Lactated Ringers
        • 7.2.1.4. Amino Acids
      • 7.2.2. Global Intravenous (IV) Solution by: Application (Value)
        • 7.2.2.1. Hospitals & Clinics
        • 7.2.2.2. Ambulatory
        • 7.2.2.3. Homecare
      • 7.2.3. Global Intravenous (IV) Solution by: Nutrition Type (Value)
        • 7.2.3.1. Carbohydrates
        • 7.2.3.2. Salts and Electrolytes
        • 7.2.3.3. Minerals
        • 7.2.3.4. Vitamins
        • 7.2.3.5. Amino Acids
      • 7.2.4. Global Intravenous (IV) Solution Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Intravenous (IV) Solution (Volume)
      • 7.3.1. Global Intravenous (IV) Solution by: Type (Volume)
        • 7.3.1.1. Saline
        • 7.3.1.2. Dextran
        • 7.3.1.3. Lactated Ringers
        • 7.3.1.4. Amino Acids
      • 7.3.2. Global Intravenous (IV) Solution by: Application (Volume)
        • 7.3.2.1. Hospitals & Clinics
        • 7.3.2.2. Ambulatory
        • 7.3.2.3. Homecare
      • 7.3.3. Global Intravenous (IV) Solution by: Nutrition Type (Volume)
        • 7.3.3.1. Carbohydrates
        • 7.3.3.2. Salts and Electrolytes
        • 7.3.3.3. Minerals
        • 7.3.3.4. Vitamins
        • 7.3.3.5. Amino Acids
      • 7.3.4. Global Intravenous (IV) Solution Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Intravenous (IV) Solution: by Type(USD Million)
  • Table 2. Intravenous (IV) Solution Saline , by Region USD Million (2018-2023)
  • Table 3. Intravenous (IV) Solution Dextran , by Region USD Million (2018-2023)
  • Table 4. Intravenous (IV) Solution Lactated Ringers , by Region USD Million (2018-2023)
  • Table 5. Intravenous (IV) Solution Amino Acids , by Region USD Million (2018-2023)
  • Table 6. Intravenous (IV) Solution: by Application(USD Million)
  • Table 7. Intravenous (IV) Solution Hospitals & Clinics , by Region USD Million (2018-2023)
  • Table 8. Intravenous (IV) Solution Ambulatory , by Region USD Million (2018-2023)
  • Table 9. Intravenous (IV) Solution Homecare , by Region USD Million (2018-2023)
  • Table 10. Intravenous (IV) Solution: by Nutrition Type(USD Million)
  • Table 11. Intravenous (IV) Solution Carbohydrates , by Region USD Million (2018-2023)
  • Table 12. Intravenous (IV) Solution Salts and Electrolytes , by Region USD Million (2018-2023)
  • Table 13. Intravenous (IV) Solution Minerals , by Region USD Million (2018-2023)
  • Table 14. Intravenous (IV) Solution Vitamins , by Region USD Million (2018-2023)
  • Table 15. Intravenous (IV) Solution Amino Acids , by Region USD Million (2018-2023)
  • Table 16. South America Intravenous (IV) Solution, by Country USD Million (2018-2023)
  • Table 17. South America Intravenous (IV) Solution, by Type USD Million (2018-2023)
  • Table 18. South America Intravenous (IV) Solution, by Application USD Million (2018-2023)
  • Table 19. South America Intravenous (IV) Solution, by Nutrition Type USD Million (2018-2023)
  • Table 20. Brazil Intravenous (IV) Solution, by Type USD Million (2018-2023)
  • Table 21. Brazil Intravenous (IV) Solution, by Application USD Million (2018-2023)
  • Table 22. Brazil Intravenous (IV) Solution, by Nutrition Type USD Million (2018-2023)
  • Table 23. Argentina Intravenous (IV) Solution, by Type USD Million (2018-2023)
  • Table 24. Argentina Intravenous (IV) Solution, by Application USD Million (2018-2023)
  • Table 25. Argentina Intravenous (IV) Solution, by Nutrition Type USD Million (2018-2023)
  • Table 26. Rest of South America Intravenous (IV) Solution, by Type USD Million (2018-2023)
  • Table 27. Rest of South America Intravenous (IV) Solution, by Application USD Million (2018-2023)
  • Table 28. Rest of South America Intravenous (IV) Solution, by Nutrition Type USD Million (2018-2023)
  • Table 29. Asia Pacific Intravenous (IV) Solution, by Country USD Million (2018-2023)
  • Table 30. Asia Pacific Intravenous (IV) Solution, by Type USD Million (2018-2023)
  • Table 31. Asia Pacific Intravenous (IV) Solution, by Application USD Million (2018-2023)
  • Table 32. Asia Pacific Intravenous (IV) Solution, by Nutrition Type USD Million (2018-2023)
  • Table 33. China Intravenous (IV) Solution, by Type USD Million (2018-2023)
  • Table 34. China Intravenous (IV) Solution, by Application USD Million (2018-2023)
  • Table 35. China Intravenous (IV) Solution, by Nutrition Type USD Million (2018-2023)
  • Table 36. Japan Intravenous (IV) Solution, by Type USD Million (2018-2023)
  • Table 37. Japan Intravenous (IV) Solution, by Application USD Million (2018-2023)
  • Table 38. Japan Intravenous (IV) Solution, by Nutrition Type USD Million (2018-2023)
  • Table 39. India Intravenous (IV) Solution, by Type USD Million (2018-2023)
  • Table 40. India Intravenous (IV) Solution, by Application USD Million (2018-2023)
  • Table 41. India Intravenous (IV) Solution, by Nutrition Type USD Million (2018-2023)
  • Table 42. South Korea Intravenous (IV) Solution, by Type USD Million (2018-2023)
  • Table 43. South Korea Intravenous (IV) Solution, by Application USD Million (2018-2023)
  • Table 44. South Korea Intravenous (IV) Solution, by Nutrition Type USD Million (2018-2023)
  • Table 45. Taiwan Intravenous (IV) Solution, by Type USD Million (2018-2023)
  • Table 46. Taiwan Intravenous (IV) Solution, by Application USD Million (2018-2023)
  • Table 47. Taiwan Intravenous (IV) Solution, by Nutrition Type USD Million (2018-2023)
  • Table 48. Australia Intravenous (IV) Solution, by Type USD Million (2018-2023)
  • Table 49. Australia Intravenous (IV) Solution, by Application USD Million (2018-2023)
  • Table 50. Australia Intravenous (IV) Solution, by Nutrition Type USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Intravenous (IV) Solution, by Type USD Million (2018-2023)
  • Table 52. Rest of Asia-Pacific Intravenous (IV) Solution, by Application USD Million (2018-2023)
  • Table 53. Rest of Asia-Pacific Intravenous (IV) Solution, by Nutrition Type USD Million (2018-2023)
  • Table 54. Europe Intravenous (IV) Solution, by Country USD Million (2018-2023)
  • Table 55. Europe Intravenous (IV) Solution, by Type USD Million (2018-2023)
  • Table 56. Europe Intravenous (IV) Solution, by Application USD Million (2018-2023)
  • Table 57. Europe Intravenous (IV) Solution, by Nutrition Type USD Million (2018-2023)
  • Table 58. Germany Intravenous (IV) Solution, by Type USD Million (2018-2023)
  • Table 59. Germany Intravenous (IV) Solution, by Application USD Million (2018-2023)
  • Table 60. Germany Intravenous (IV) Solution, by Nutrition Type USD Million (2018-2023)
  • Table 61. France Intravenous (IV) Solution, by Type USD Million (2018-2023)
  • Table 62. France Intravenous (IV) Solution, by Application USD Million (2018-2023)
  • Table 63. France Intravenous (IV) Solution, by Nutrition Type USD Million (2018-2023)
  • Table 64. Italy Intravenous (IV) Solution, by Type USD Million (2018-2023)
  • Table 65. Italy Intravenous (IV) Solution, by Application USD Million (2018-2023)
  • Table 66. Italy Intravenous (IV) Solution, by Nutrition Type USD Million (2018-2023)
  • Table 67. United Kingdom Intravenous (IV) Solution, by Type USD Million (2018-2023)
  • Table 68. United Kingdom Intravenous (IV) Solution, by Application USD Million (2018-2023)
  • Table 69. United Kingdom Intravenous (IV) Solution, by Nutrition Type USD Million (2018-2023)
  • Table 70. Netherlands Intravenous (IV) Solution, by Type USD Million (2018-2023)
  • Table 71. Netherlands Intravenous (IV) Solution, by Application USD Million (2018-2023)
  • Table 72. Netherlands Intravenous (IV) Solution, by Nutrition Type USD Million (2018-2023)
  • Table 73. Rest of Europe Intravenous (IV) Solution, by Type USD Million (2018-2023)
  • Table 74. Rest of Europe Intravenous (IV) Solution, by Application USD Million (2018-2023)
  • Table 75. Rest of Europe Intravenous (IV) Solution, by Nutrition Type USD Million (2018-2023)
  • Table 76. MEA Intravenous (IV) Solution, by Country USD Million (2018-2023)
  • Table 77. MEA Intravenous (IV) Solution, by Type USD Million (2018-2023)
  • Table 78. MEA Intravenous (IV) Solution, by Application USD Million (2018-2023)
  • Table 79. MEA Intravenous (IV) Solution, by Nutrition Type USD Million (2018-2023)
  • Table 80. Middle East Intravenous (IV) Solution, by Type USD Million (2018-2023)
  • Table 81. Middle East Intravenous (IV) Solution, by Application USD Million (2018-2023)
  • Table 82. Middle East Intravenous (IV) Solution, by Nutrition Type USD Million (2018-2023)
  • Table 83. Africa Intravenous (IV) Solution, by Type USD Million (2018-2023)
  • Table 84. Africa Intravenous (IV) Solution, by Application USD Million (2018-2023)
  • Table 85. Africa Intravenous (IV) Solution, by Nutrition Type USD Million (2018-2023)
  • Table 86. North America Intravenous (IV) Solution, by Country USD Million (2018-2023)
  • Table 87. North America Intravenous (IV) Solution, by Type USD Million (2018-2023)
  • Table 88. North America Intravenous (IV) Solution, by Application USD Million (2018-2023)
  • Table 89. North America Intravenous (IV) Solution, by Nutrition Type USD Million (2018-2023)
  • Table 90. United States Intravenous (IV) Solution, by Type USD Million (2018-2023)
  • Table 91. United States Intravenous (IV) Solution, by Application USD Million (2018-2023)
  • Table 92. United States Intravenous (IV) Solution, by Nutrition Type USD Million (2018-2023)
  • Table 93. Canada Intravenous (IV) Solution, by Type USD Million (2018-2023)
  • Table 94. Canada Intravenous (IV) Solution, by Application USD Million (2018-2023)
  • Table 95. Canada Intravenous (IV) Solution, by Nutrition Type USD Million (2018-2023)
  • Table 96. Mexico Intravenous (IV) Solution, by Type USD Million (2018-2023)
  • Table 97. Mexico Intravenous (IV) Solution, by Application USD Million (2018-2023)
  • Table 98. Mexico Intravenous (IV) Solution, by Nutrition Type USD Million (2018-2023)
  • Table 99. Intravenous (IV) Solution Sales: by Type(K Units)
  • Table 100. Intravenous (IV) Solution Sales Saline , by Region K Units (2018-2023)
  • Table 101. Intravenous (IV) Solution Sales Dextran , by Region K Units (2018-2023)
  • Table 102. Intravenous (IV) Solution Sales Lactated Ringers , by Region K Units (2018-2023)
  • Table 103. Intravenous (IV) Solution Sales Amino Acids , by Region K Units (2018-2023)
  • Table 104. Intravenous (IV) Solution Sales: by Application(K Units)
  • Table 105. Intravenous (IV) Solution Sales Hospitals & Clinics , by Region K Units (2018-2023)
  • Table 106. Intravenous (IV) Solution Sales Ambulatory , by Region K Units (2018-2023)
  • Table 107. Intravenous (IV) Solution Sales Homecare , by Region K Units (2018-2023)
  • Table 108. Intravenous (IV) Solution Sales: by Nutrition Type(K Units)
  • Table 109. Intravenous (IV) Solution Sales Carbohydrates , by Region K Units (2018-2023)
  • Table 110. Intravenous (IV) Solution Sales Salts and Electrolytes , by Region K Units (2018-2023)
  • Table 111. Intravenous (IV) Solution Sales Minerals , by Region K Units (2018-2023)
  • Table 112. Intravenous (IV) Solution Sales Vitamins , by Region K Units (2018-2023)
  • Table 113. Intravenous (IV) Solution Sales Amino Acids , by Region K Units (2018-2023)
  • Table 114. South America Intravenous (IV) Solution Sales, by Country K Units (2018-2023)
  • Table 115. South America Intravenous (IV) Solution Sales, by Type K Units (2018-2023)
  • Table 116. South America Intravenous (IV) Solution Sales, by Application K Units (2018-2023)
  • Table 117. South America Intravenous (IV) Solution Sales, by Nutrition Type K Units (2018-2023)
  • Table 118. Brazil Intravenous (IV) Solution Sales, by Type K Units (2018-2023)
  • Table 119. Brazil Intravenous (IV) Solution Sales, by Application K Units (2018-2023)
  • Table 120. Brazil Intravenous (IV) Solution Sales, by Nutrition Type K Units (2018-2023)
  • Table 121. Argentina Intravenous (IV) Solution Sales, by Type K Units (2018-2023)
  • Table 122. Argentina Intravenous (IV) Solution Sales, by Application K Units (2018-2023)
  • Table 123. Argentina Intravenous (IV) Solution Sales, by Nutrition Type K Units (2018-2023)
  • Table 124. Rest of South America Intravenous (IV) Solution Sales, by Type K Units (2018-2023)
  • Table 125. Rest of South America Intravenous (IV) Solution Sales, by Application K Units (2018-2023)
  • Table 126. Rest of South America Intravenous (IV) Solution Sales, by Nutrition Type K Units (2018-2023)
  • Table 127. Asia Pacific Intravenous (IV) Solution Sales, by Country K Units (2018-2023)
  • Table 128. Asia Pacific Intravenous (IV) Solution Sales, by Type K Units (2018-2023)
  • Table 129. Asia Pacific Intravenous (IV) Solution Sales, by Application K Units (2018-2023)
  • Table 130. Asia Pacific Intravenous (IV) Solution Sales, by Nutrition Type K Units (2018-2023)
  • Table 131. China Intravenous (IV) Solution Sales, by Type K Units (2018-2023)
  • Table 132. China Intravenous (IV) Solution Sales, by Application K Units (2018-2023)
  • Table 133. China Intravenous (IV) Solution Sales, by Nutrition Type K Units (2018-2023)
  • Table 134. Japan Intravenous (IV) Solution Sales, by Type K Units (2018-2023)
  • Table 135. Japan Intravenous (IV) Solution Sales, by Application K Units (2018-2023)
  • Table 136. Japan Intravenous (IV) Solution Sales, by Nutrition Type K Units (2018-2023)
  • Table 137. India Intravenous (IV) Solution Sales, by Type K Units (2018-2023)
  • Table 138. India Intravenous (IV) Solution Sales, by Application K Units (2018-2023)
  • Table 139. India Intravenous (IV) Solution Sales, by Nutrition Type K Units (2018-2023)
  • Table 140. South Korea Intravenous (IV) Solution Sales, by Type K Units (2018-2023)
  • Table 141. South Korea Intravenous (IV) Solution Sales, by Application K Units (2018-2023)
  • Table 142. South Korea Intravenous (IV) Solution Sales, by Nutrition Type K Units (2018-2023)
  • Table 143. Taiwan Intravenous (IV) Solution Sales, by Type K Units (2018-2023)
  • Table 144. Taiwan Intravenous (IV) Solution Sales, by Application K Units (2018-2023)
  • Table 145. Taiwan Intravenous (IV) Solution Sales, by Nutrition Type K Units (2018-2023)
  • Table 146. Australia Intravenous (IV) Solution Sales, by Type K Units (2018-2023)
  • Table 147. Australia Intravenous (IV) Solution Sales, by Application K Units (2018-2023)
  • Table 148. Australia Intravenous (IV) Solution Sales, by Nutrition Type K Units (2018-2023)
  • Table 149. Rest of Asia-Pacific Intravenous (IV) Solution Sales, by Type K Units (2018-2023)
  • Table 150. Rest of Asia-Pacific Intravenous (IV) Solution Sales, by Application K Units (2018-2023)
  • Table 151. Rest of Asia-Pacific Intravenous (IV) Solution Sales, by Nutrition Type K Units (2018-2023)
  • Table 152. Europe Intravenous (IV) Solution Sales, by Country K Units (2018-2023)
  • Table 153. Europe Intravenous (IV) Solution Sales, by Type K Units (2018-2023)
  • Table 154. Europe Intravenous (IV) Solution Sales, by Application K Units (2018-2023)
  • Table 155. Europe Intravenous (IV) Solution Sales, by Nutrition Type K Units (2018-2023)
  • Table 156. Germany Intravenous (IV) Solution Sales, by Type K Units (2018-2023)
  • Table 157. Germany Intravenous (IV) Solution Sales, by Application K Units (2018-2023)
  • Table 158. Germany Intravenous (IV) Solution Sales, by Nutrition Type K Units (2018-2023)
  • Table 159. France Intravenous (IV) Solution Sales, by Type K Units (2018-2023)
  • Table 160. France Intravenous (IV) Solution Sales, by Application K Units (2018-2023)
  • Table 161. France Intravenous (IV) Solution Sales, by Nutrition Type K Units (2018-2023)
  • Table 162. Italy Intravenous (IV) Solution Sales, by Type K Units (2018-2023)
  • Table 163. Italy Intravenous (IV) Solution Sales, by Application K Units (2018-2023)
  • Table 164. Italy Intravenous (IV) Solution Sales, by Nutrition Type K Units (2018-2023)
  • Table 165. United Kingdom Intravenous (IV) Solution Sales, by Type K Units (2018-2023)
  • Table 166. United Kingdom Intravenous (IV) Solution Sales, by Application K Units (2018-2023)
  • Table 167. United Kingdom Intravenous (IV) Solution Sales, by Nutrition Type K Units (2018-2023)
  • Table 168. Netherlands Intravenous (IV) Solution Sales, by Type K Units (2018-2023)
  • Table 169. Netherlands Intravenous (IV) Solution Sales, by Application K Units (2018-2023)
  • Table 170. Netherlands Intravenous (IV) Solution Sales, by Nutrition Type K Units (2018-2023)
  • Table 171. Rest of Europe Intravenous (IV) Solution Sales, by Type K Units (2018-2023)
  • Table 172. Rest of Europe Intravenous (IV) Solution Sales, by Application K Units (2018-2023)
  • Table 173. Rest of Europe Intravenous (IV) Solution Sales, by Nutrition Type K Units (2018-2023)
  • Table 174. MEA Intravenous (IV) Solution Sales, by Country K Units (2018-2023)
  • Table 175. MEA Intravenous (IV) Solution Sales, by Type K Units (2018-2023)
  • Table 176. MEA Intravenous (IV) Solution Sales, by Application K Units (2018-2023)
  • Table 177. MEA Intravenous (IV) Solution Sales, by Nutrition Type K Units (2018-2023)
  • Table 178. Middle East Intravenous (IV) Solution Sales, by Type K Units (2018-2023)
  • Table 179. Middle East Intravenous (IV) Solution Sales, by Application K Units (2018-2023)
  • Table 180. Middle East Intravenous (IV) Solution Sales, by Nutrition Type K Units (2018-2023)
  • Table 181. Africa Intravenous (IV) Solution Sales, by Type K Units (2018-2023)
  • Table 182. Africa Intravenous (IV) Solution Sales, by Application K Units (2018-2023)
  • Table 183. Africa Intravenous (IV) Solution Sales, by Nutrition Type K Units (2018-2023)
  • Table 184. North America Intravenous (IV) Solution Sales, by Country K Units (2018-2023)
  • Table 185. North America Intravenous (IV) Solution Sales, by Type K Units (2018-2023)
  • Table 186. North America Intravenous (IV) Solution Sales, by Application K Units (2018-2023)
  • Table 187. North America Intravenous (IV) Solution Sales, by Nutrition Type K Units (2018-2023)
  • Table 188. United States Intravenous (IV) Solution Sales, by Type K Units (2018-2023)
  • Table 189. United States Intravenous (IV) Solution Sales, by Application K Units (2018-2023)
  • Table 190. United States Intravenous (IV) Solution Sales, by Nutrition Type K Units (2018-2023)
  • Table 191. Canada Intravenous (IV) Solution Sales, by Type K Units (2018-2023)
  • Table 192. Canada Intravenous (IV) Solution Sales, by Application K Units (2018-2023)
  • Table 193. Canada Intravenous (IV) Solution Sales, by Nutrition Type K Units (2018-2023)
  • Table 194. Mexico Intravenous (IV) Solution Sales, by Type K Units (2018-2023)
  • Table 195. Mexico Intravenous (IV) Solution Sales, by Application K Units (2018-2023)
  • Table 196. Mexico Intravenous (IV) Solution Sales, by Nutrition Type K Units (2018-2023)
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Company Basic Information, Sales Area and Its Competitors
  • Table 205. Intravenous (IV) Solution: by Type(USD Million)
  • Table 206. Intravenous (IV) Solution Saline , by Region USD Million (2025-2030)
  • Table 207. Intravenous (IV) Solution Dextran , by Region USD Million (2025-2030)
  • Table 208. Intravenous (IV) Solution Lactated Ringers , by Region USD Million (2025-2030)
  • Table 209. Intravenous (IV) Solution Amino Acids , by Region USD Million (2025-2030)
  • Table 210. Intravenous (IV) Solution: by Application(USD Million)
  • Table 211. Intravenous (IV) Solution Hospitals & Clinics , by Region USD Million (2025-2030)
  • Table 212. Intravenous (IV) Solution Ambulatory , by Region USD Million (2025-2030)
  • Table 213. Intravenous (IV) Solution Homecare , by Region USD Million (2025-2030)
  • Table 214. Intravenous (IV) Solution: by Nutrition Type(USD Million)
  • Table 215. Intravenous (IV) Solution Carbohydrates , by Region USD Million (2025-2030)
  • Table 216. Intravenous (IV) Solution Salts and Electrolytes , by Region USD Million (2025-2030)
  • Table 217. Intravenous (IV) Solution Minerals , by Region USD Million (2025-2030)
  • Table 218. Intravenous (IV) Solution Vitamins , by Region USD Million (2025-2030)
  • Table 219. Intravenous (IV) Solution Amino Acids , by Region USD Million (2025-2030)
  • Table 220. South America Intravenous (IV) Solution, by Country USD Million (2025-2030)
  • Table 221. South America Intravenous (IV) Solution, by Type USD Million (2025-2030)
  • Table 222. South America Intravenous (IV) Solution, by Application USD Million (2025-2030)
  • Table 223. South America Intravenous (IV) Solution, by Nutrition Type USD Million (2025-2030)
  • Table 224. Brazil Intravenous (IV) Solution, by Type USD Million (2025-2030)
  • Table 225. Brazil Intravenous (IV) Solution, by Application USD Million (2025-2030)
  • Table 226. Brazil Intravenous (IV) Solution, by Nutrition Type USD Million (2025-2030)
  • Table 227. Argentina Intravenous (IV) Solution, by Type USD Million (2025-2030)
  • Table 228. Argentina Intravenous (IV) Solution, by Application USD Million (2025-2030)
  • Table 229. Argentina Intravenous (IV) Solution, by Nutrition Type USD Million (2025-2030)
  • Table 230. Rest of South America Intravenous (IV) Solution, by Type USD Million (2025-2030)
  • Table 231. Rest of South America Intravenous (IV) Solution, by Application USD Million (2025-2030)
  • Table 232. Rest of South America Intravenous (IV) Solution, by Nutrition Type USD Million (2025-2030)
  • Table 233. Asia Pacific Intravenous (IV) Solution, by Country USD Million (2025-2030)
  • Table 234. Asia Pacific Intravenous (IV) Solution, by Type USD Million (2025-2030)
  • Table 235. Asia Pacific Intravenous (IV) Solution, by Application USD Million (2025-2030)
  • Table 236. Asia Pacific Intravenous (IV) Solution, by Nutrition Type USD Million (2025-2030)
  • Table 237. China Intravenous (IV) Solution, by Type USD Million (2025-2030)
  • Table 238. China Intravenous (IV) Solution, by Application USD Million (2025-2030)
  • Table 239. China Intravenous (IV) Solution, by Nutrition Type USD Million (2025-2030)
  • Table 240. Japan Intravenous (IV) Solution, by Type USD Million (2025-2030)
  • Table 241. Japan Intravenous (IV) Solution, by Application USD Million (2025-2030)
  • Table 242. Japan Intravenous (IV) Solution, by Nutrition Type USD Million (2025-2030)
  • Table 243. India Intravenous (IV) Solution, by Type USD Million (2025-2030)
  • Table 244. India Intravenous (IV) Solution, by Application USD Million (2025-2030)
  • Table 245. India Intravenous (IV) Solution, by Nutrition Type USD Million (2025-2030)
  • Table 246. South Korea Intravenous (IV) Solution, by Type USD Million (2025-2030)
  • Table 247. South Korea Intravenous (IV) Solution, by Application USD Million (2025-2030)
  • Table 248. South Korea Intravenous (IV) Solution, by Nutrition Type USD Million (2025-2030)
  • Table 249. Taiwan Intravenous (IV) Solution, by Type USD Million (2025-2030)
  • Table 250. Taiwan Intravenous (IV) Solution, by Application USD Million (2025-2030)
  • Table 251. Taiwan Intravenous (IV) Solution, by Nutrition Type USD Million (2025-2030)
  • Table 252. Australia Intravenous (IV) Solution, by Type USD Million (2025-2030)
  • Table 253. Australia Intravenous (IV) Solution, by Application USD Million (2025-2030)
  • Table 254. Australia Intravenous (IV) Solution, by Nutrition Type USD Million (2025-2030)
  • Table 255. Rest of Asia-Pacific Intravenous (IV) Solution, by Type USD Million (2025-2030)
  • Table 256. Rest of Asia-Pacific Intravenous (IV) Solution, by Application USD Million (2025-2030)
  • Table 257. Rest of Asia-Pacific Intravenous (IV) Solution, by Nutrition Type USD Million (2025-2030)
  • Table 258. Europe Intravenous (IV) Solution, by Country USD Million (2025-2030)
  • Table 259. Europe Intravenous (IV) Solution, by Type USD Million (2025-2030)
  • Table 260. Europe Intravenous (IV) Solution, by Application USD Million (2025-2030)
  • Table 261. Europe Intravenous (IV) Solution, by Nutrition Type USD Million (2025-2030)
  • Table 262. Germany Intravenous (IV) Solution, by Type USD Million (2025-2030)
  • Table 263. Germany Intravenous (IV) Solution, by Application USD Million (2025-2030)
  • Table 264. Germany Intravenous (IV) Solution, by Nutrition Type USD Million (2025-2030)
  • Table 265. France Intravenous (IV) Solution, by Type USD Million (2025-2030)
  • Table 266. France Intravenous (IV) Solution, by Application USD Million (2025-2030)
  • Table 267. France Intravenous (IV) Solution, by Nutrition Type USD Million (2025-2030)
  • Table 268. Italy Intravenous (IV) Solution, by Type USD Million (2025-2030)
  • Table 269. Italy Intravenous (IV) Solution, by Application USD Million (2025-2030)
  • Table 270. Italy Intravenous (IV) Solution, by Nutrition Type USD Million (2025-2030)
  • Table 271. United Kingdom Intravenous (IV) Solution, by Type USD Million (2025-2030)
  • Table 272. United Kingdom Intravenous (IV) Solution, by Application USD Million (2025-2030)
  • Table 273. United Kingdom Intravenous (IV) Solution, by Nutrition Type USD Million (2025-2030)
  • Table 274. Netherlands Intravenous (IV) Solution, by Type USD Million (2025-2030)
  • Table 275. Netherlands Intravenous (IV) Solution, by Application USD Million (2025-2030)
  • Table 276. Netherlands Intravenous (IV) Solution, by Nutrition Type USD Million (2025-2030)
  • Table 277. Rest of Europe Intravenous (IV) Solution, by Type USD Million (2025-2030)
  • Table 278. Rest of Europe Intravenous (IV) Solution, by Application USD Million (2025-2030)
  • Table 279. Rest of Europe Intravenous (IV) Solution, by Nutrition Type USD Million (2025-2030)
  • Table 280. MEA Intravenous (IV) Solution, by Country USD Million (2025-2030)
  • Table 281. MEA Intravenous (IV) Solution, by Type USD Million (2025-2030)
  • Table 282. MEA Intravenous (IV) Solution, by Application USD Million (2025-2030)
  • Table 283. MEA Intravenous (IV) Solution, by Nutrition Type USD Million (2025-2030)
  • Table 284. Middle East Intravenous (IV) Solution, by Type USD Million (2025-2030)
  • Table 285. Middle East Intravenous (IV) Solution, by Application USD Million (2025-2030)
  • Table 286. Middle East Intravenous (IV) Solution, by Nutrition Type USD Million (2025-2030)
  • Table 287. Africa Intravenous (IV) Solution, by Type USD Million (2025-2030)
  • Table 288. Africa Intravenous (IV) Solution, by Application USD Million (2025-2030)
  • Table 289. Africa Intravenous (IV) Solution, by Nutrition Type USD Million (2025-2030)
  • Table 290. North America Intravenous (IV) Solution, by Country USD Million (2025-2030)
  • Table 291. North America Intravenous (IV) Solution, by Type USD Million (2025-2030)
  • Table 292. North America Intravenous (IV) Solution, by Application USD Million (2025-2030)
  • Table 293. North America Intravenous (IV) Solution, by Nutrition Type USD Million (2025-2030)
  • Table 294. United States Intravenous (IV) Solution, by Type USD Million (2025-2030)
  • Table 295. United States Intravenous (IV) Solution, by Application USD Million (2025-2030)
  • Table 296. United States Intravenous (IV) Solution, by Nutrition Type USD Million (2025-2030)
  • Table 297. Canada Intravenous (IV) Solution, by Type USD Million (2025-2030)
  • Table 298. Canada Intravenous (IV) Solution, by Application USD Million (2025-2030)
  • Table 299. Canada Intravenous (IV) Solution, by Nutrition Type USD Million (2025-2030)
  • Table 300. Mexico Intravenous (IV) Solution, by Type USD Million (2025-2030)
  • Table 301. Mexico Intravenous (IV) Solution, by Application USD Million (2025-2030)
  • Table 302. Mexico Intravenous (IV) Solution, by Nutrition Type USD Million (2025-2030)
  • Table 303. Intravenous (IV) Solution Sales: by Type(K Units)
  • Table 304. Intravenous (IV) Solution Sales Saline , by Region K Units (2025-2030)
  • Table 305. Intravenous (IV) Solution Sales Dextran , by Region K Units (2025-2030)
  • Table 306. Intravenous (IV) Solution Sales Lactated Ringers , by Region K Units (2025-2030)
  • Table 307. Intravenous (IV) Solution Sales Amino Acids , by Region K Units (2025-2030)
  • Table 308. Intravenous (IV) Solution Sales: by Application(K Units)
  • Table 309. Intravenous (IV) Solution Sales Hospitals & Clinics , by Region K Units (2025-2030)
  • Table 310. Intravenous (IV) Solution Sales Ambulatory , by Region K Units (2025-2030)
  • Table 311. Intravenous (IV) Solution Sales Homecare , by Region K Units (2025-2030)
  • Table 312. Intravenous (IV) Solution Sales: by Nutrition Type(K Units)
  • Table 313. Intravenous (IV) Solution Sales Carbohydrates , by Region K Units (2025-2030)
  • Table 314. Intravenous (IV) Solution Sales Salts and Electrolytes , by Region K Units (2025-2030)
  • Table 315. Intravenous (IV) Solution Sales Minerals , by Region K Units (2025-2030)
  • Table 316. Intravenous (IV) Solution Sales Vitamins , by Region K Units (2025-2030)
  • Table 317. Intravenous (IV) Solution Sales Amino Acids , by Region K Units (2025-2030)
  • Table 318. South America Intravenous (IV) Solution Sales, by Country K Units (2025-2030)
  • Table 319. South America Intravenous (IV) Solution Sales, by Type K Units (2025-2030)
  • Table 320. South America Intravenous (IV) Solution Sales, by Application K Units (2025-2030)
  • Table 321. South America Intravenous (IV) Solution Sales, by Nutrition Type K Units (2025-2030)
  • Table 322. Brazil Intravenous (IV) Solution Sales, by Type K Units (2025-2030)
  • Table 323. Brazil Intravenous (IV) Solution Sales, by Application K Units (2025-2030)
  • Table 324. Brazil Intravenous (IV) Solution Sales, by Nutrition Type K Units (2025-2030)
  • Table 325. Argentina Intravenous (IV) Solution Sales, by Type K Units (2025-2030)
  • Table 326. Argentina Intravenous (IV) Solution Sales, by Application K Units (2025-2030)
  • Table 327. Argentina Intravenous (IV) Solution Sales, by Nutrition Type K Units (2025-2030)
  • Table 328. Rest of South America Intravenous (IV) Solution Sales, by Type K Units (2025-2030)
  • Table 329. Rest of South America Intravenous (IV) Solution Sales, by Application K Units (2025-2030)
  • Table 330. Rest of South America Intravenous (IV) Solution Sales, by Nutrition Type K Units (2025-2030)
  • Table 331. Asia Pacific Intravenous (IV) Solution Sales, by Country K Units (2025-2030)
  • Table 332. Asia Pacific Intravenous (IV) Solution Sales, by Type K Units (2025-2030)
  • Table 333. Asia Pacific Intravenous (IV) Solution Sales, by Application K Units (2025-2030)
  • Table 334. Asia Pacific Intravenous (IV) Solution Sales, by Nutrition Type K Units (2025-2030)
  • Table 335. China Intravenous (IV) Solution Sales, by Type K Units (2025-2030)
  • Table 336. China Intravenous (IV) Solution Sales, by Application K Units (2025-2030)
  • Table 337. China Intravenous (IV) Solution Sales, by Nutrition Type K Units (2025-2030)
  • Table 338. Japan Intravenous (IV) Solution Sales, by Type K Units (2025-2030)
  • Table 339. Japan Intravenous (IV) Solution Sales, by Application K Units (2025-2030)
  • Table 340. Japan Intravenous (IV) Solution Sales, by Nutrition Type K Units (2025-2030)
  • Table 341. India Intravenous (IV) Solution Sales, by Type K Units (2025-2030)
  • Table 342. India Intravenous (IV) Solution Sales, by Application K Units (2025-2030)
  • Table 343. India Intravenous (IV) Solution Sales, by Nutrition Type K Units (2025-2030)
  • Table 344. South Korea Intravenous (IV) Solution Sales, by Type K Units (2025-2030)
  • Table 345. South Korea Intravenous (IV) Solution Sales, by Application K Units (2025-2030)
  • Table 346. South Korea Intravenous (IV) Solution Sales, by Nutrition Type K Units (2025-2030)
  • Table 347. Taiwan Intravenous (IV) Solution Sales, by Type K Units (2025-2030)
  • Table 348. Taiwan Intravenous (IV) Solution Sales, by Application K Units (2025-2030)
  • Table 349. Taiwan Intravenous (IV) Solution Sales, by Nutrition Type K Units (2025-2030)
  • Table 350. Australia Intravenous (IV) Solution Sales, by Type K Units (2025-2030)
  • Table 351. Australia Intravenous (IV) Solution Sales, by Application K Units (2025-2030)
  • Table 352. Australia Intravenous (IV) Solution Sales, by Nutrition Type K Units (2025-2030)
  • Table 353. Rest of Asia-Pacific Intravenous (IV) Solution Sales, by Type K Units (2025-2030)
  • Table 354. Rest of Asia-Pacific Intravenous (IV) Solution Sales, by Application K Units (2025-2030)
  • Table 355. Rest of Asia-Pacific Intravenous (IV) Solution Sales, by Nutrition Type K Units (2025-2030)
  • Table 356. Europe Intravenous (IV) Solution Sales, by Country K Units (2025-2030)
  • Table 357. Europe Intravenous (IV) Solution Sales, by Type K Units (2025-2030)
  • Table 358. Europe Intravenous (IV) Solution Sales, by Application K Units (2025-2030)
  • Table 359. Europe Intravenous (IV) Solution Sales, by Nutrition Type K Units (2025-2030)
  • Table 360. Germany Intravenous (IV) Solution Sales, by Type K Units (2025-2030)
  • Table 361. Germany Intravenous (IV) Solution Sales, by Application K Units (2025-2030)
  • Table 362. Germany Intravenous (IV) Solution Sales, by Nutrition Type K Units (2025-2030)
  • Table 363. France Intravenous (IV) Solution Sales, by Type K Units (2025-2030)
  • Table 364. France Intravenous (IV) Solution Sales, by Application K Units (2025-2030)
  • Table 365. France Intravenous (IV) Solution Sales, by Nutrition Type K Units (2025-2030)
  • Table 366. Italy Intravenous (IV) Solution Sales, by Type K Units (2025-2030)
  • Table 367. Italy Intravenous (IV) Solution Sales, by Application K Units (2025-2030)
  • Table 368. Italy Intravenous (IV) Solution Sales, by Nutrition Type K Units (2025-2030)
  • Table 369. United Kingdom Intravenous (IV) Solution Sales, by Type K Units (2025-2030)
  • Table 370. United Kingdom Intravenous (IV) Solution Sales, by Application K Units (2025-2030)
  • Table 371. United Kingdom Intravenous (IV) Solution Sales, by Nutrition Type K Units (2025-2030)
  • Table 372. Netherlands Intravenous (IV) Solution Sales, by Type K Units (2025-2030)
  • Table 373. Netherlands Intravenous (IV) Solution Sales, by Application K Units (2025-2030)
  • Table 374. Netherlands Intravenous (IV) Solution Sales, by Nutrition Type K Units (2025-2030)
  • Table 375. Rest of Europe Intravenous (IV) Solution Sales, by Type K Units (2025-2030)
  • Table 376. Rest of Europe Intravenous (IV) Solution Sales, by Application K Units (2025-2030)
  • Table 377. Rest of Europe Intravenous (IV) Solution Sales, by Nutrition Type K Units (2025-2030)
  • Table 378. MEA Intravenous (IV) Solution Sales, by Country K Units (2025-2030)
  • Table 379. MEA Intravenous (IV) Solution Sales, by Type K Units (2025-2030)
  • Table 380. MEA Intravenous (IV) Solution Sales, by Application K Units (2025-2030)
  • Table 381. MEA Intravenous (IV) Solution Sales, by Nutrition Type K Units (2025-2030)
  • Table 382. Middle East Intravenous (IV) Solution Sales, by Type K Units (2025-2030)
  • Table 383. Middle East Intravenous (IV) Solution Sales, by Application K Units (2025-2030)
  • Table 384. Middle East Intravenous (IV) Solution Sales, by Nutrition Type K Units (2025-2030)
  • Table 385. Africa Intravenous (IV) Solution Sales, by Type K Units (2025-2030)
  • Table 386. Africa Intravenous (IV) Solution Sales, by Application K Units (2025-2030)
  • Table 387. Africa Intravenous (IV) Solution Sales, by Nutrition Type K Units (2025-2030)
  • Table 388. North America Intravenous (IV) Solution Sales, by Country K Units (2025-2030)
  • Table 389. North America Intravenous (IV) Solution Sales, by Type K Units (2025-2030)
  • Table 390. North America Intravenous (IV) Solution Sales, by Application K Units (2025-2030)
  • Table 391. North America Intravenous (IV) Solution Sales, by Nutrition Type K Units (2025-2030)
  • Table 392. United States Intravenous (IV) Solution Sales, by Type K Units (2025-2030)
  • Table 393. United States Intravenous (IV) Solution Sales, by Application K Units (2025-2030)
  • Table 394. United States Intravenous (IV) Solution Sales, by Nutrition Type K Units (2025-2030)
  • Table 395. Canada Intravenous (IV) Solution Sales, by Type K Units (2025-2030)
  • Table 396. Canada Intravenous (IV) Solution Sales, by Application K Units (2025-2030)
  • Table 397. Canada Intravenous (IV) Solution Sales, by Nutrition Type K Units (2025-2030)
  • Table 398. Mexico Intravenous (IV) Solution Sales, by Type K Units (2025-2030)
  • Table 399. Mexico Intravenous (IV) Solution Sales, by Application K Units (2025-2030)
  • Table 400. Mexico Intravenous (IV) Solution Sales, by Nutrition Type K Units (2025-2030)
  • Table 401. Research Programs/Design for This Report
  • Table 402. Key Data Information from Secondary Sources
  • Table 403. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Intravenous (IV) Solution: by Type USD Million (2018-2023)
  • Figure 5. Global Intravenous (IV) Solution: by Application USD Million (2018-2023)
  • Figure 6. Global Intravenous (IV) Solution: by Nutrition Type USD Million (2018-2023)
  • Figure 7. South America Intravenous (IV) Solution Share (%), by Country
  • Figure 8. Asia Pacific Intravenous (IV) Solution Share (%), by Country
  • Figure 9. Europe Intravenous (IV) Solution Share (%), by Country
  • Figure 10. MEA Intravenous (IV) Solution Share (%), by Country
  • Figure 11. North America Intravenous (IV) Solution Share (%), by Country
  • Figure 12. Global Intravenous (IV) Solution: by Type K Units (2018-2023)
  • Figure 13. Global Intravenous (IV) Solution: by Application K Units (2018-2023)
  • Figure 14. Global Intravenous (IV) Solution: by Nutrition Type K Units (2018-2023)
  • Figure 15. South America Intravenous (IV) Solution Share (%), by Country
  • Figure 16. Asia Pacific Intravenous (IV) Solution Share (%), by Country
  • Figure 17. Europe Intravenous (IV) Solution Share (%), by Country
  • Figure 18. MEA Intravenous (IV) Solution Share (%), by Country
  • Figure 19. North America Intravenous (IV) Solution Share (%), by Country
  • Figure 20. Global Intravenous (IV) Solution share by Players 2023 (%)
  • Figure 21. Global Intravenous (IV) Solution share by Players (Top 3) 2023(%)
  • Figure 22. Global Intravenous (IV) Solution share by Players (Top 5) 2023(%)
  • Figure 23. BCG Matrix for key Companies
  • Figure 24. Baxter International Inc.(United States) Revenue, Net Income and Gross profit
  • Figure 25. Baxter International Inc.(United States) Revenue: by Geography 2023
  • Figure 26. ICU Medical Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. ICU Medical Inc. (United States) Revenue: by Geography 2023
  • Figure 28. B. Braun Melsungen AG (Germany) Revenue, Net Income and Gross profit
  • Figure 29. B. Braun Melsungen AG (Germany) Revenue: by Geography 2023
  • Figure 30. Grifols, S.A. (Spain) Revenue, Net Income and Gross profit
  • Figure 31. Grifols, S.A. (Spain) Revenue: by Geography 2023
  • Figure 32. Fresenius Kabi USA, LLC (United States) Revenue, Net Income and Gross profit
  • Figure 33. Fresenius Kabi USA, LLC (United States) Revenue: by Geography 2023
  • Figure 34. Vifor Pharma Management Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 35. Vifor Pharma Management Ltd (Switzerland) Revenue: by Geography 2023
  • Figure 36. JW Life Science (South Korea) Revenue, Net Income and Gross profit
  • Figure 37. JW Life Science (South Korea) Revenue: by Geography 2023
  • Figure 38. Amanta Healthcare (India) Revenue, Net Income and Gross profit
  • Figure 39. Amanta Healthcare (India) Revenue: by Geography 2023
  • Figure 40. Global Intravenous (IV) Solution: by Type USD Million (2025-2030)
  • Figure 41. Global Intravenous (IV) Solution: by Application USD Million (2025-2030)
  • Figure 42. Global Intravenous (IV) Solution: by Nutrition Type USD Million (2025-2030)
  • Figure 43. South America Intravenous (IV) Solution Share (%), by Country
  • Figure 44. Asia Pacific Intravenous (IV) Solution Share (%), by Country
  • Figure 45. Europe Intravenous (IV) Solution Share (%), by Country
  • Figure 46. MEA Intravenous (IV) Solution Share (%), by Country
  • Figure 47. North America Intravenous (IV) Solution Share (%), by Country
  • Figure 48. Global Intravenous (IV) Solution: by Type K Units (2025-2030)
  • Figure 49. Global Intravenous (IV) Solution: by Application K Units (2025-2030)
  • Figure 50. Global Intravenous (IV) Solution: by Nutrition Type K Units (2025-2030)
  • Figure 51. South America Intravenous (IV) Solution Share (%), by Country
  • Figure 52. Asia Pacific Intravenous (IV) Solution Share (%), by Country
  • Figure 53. Europe Intravenous (IV) Solution Share (%), by Country
  • Figure 54. MEA Intravenous (IV) Solution Share (%), by Country
  • Figure 55. North America Intravenous (IV) Solution Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Baxter International Inc.(United States)
  • ICU Medical Inc. (United States)
  • B. Braun Melsungen AG (Germany)
  • Grifols, S.A. (Spain)
  • Fresenius Kabi USA, LLC (United States)
  • Vifor Pharma Management Ltd (Switzerland)
  • JW Life Science (South Korea)
  • Amanta Healthcare (India)
Additional players considered in the study are as follows:
Fresenius Kabi (Germany) , Baxter (United States) , Terumo Medical Corporation (Japan) , Grifols (Spain)
Select User Access Type

Key Highlights of Report


Feb 2024 220 Pages 72 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Intravenous (IV) Solution Quantitative research analysis
Global Intravenous (IV) Solution Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Intravenous (IV) Solution Market are by type [Saline, Dextran, Lactated Ringers and Amino Acids], by end use application [Hospitals & Clinics, Ambulatory and Homecare].
The Intravenous (IV) Solution Market is gaining popularity and expected to see strong valuation by 2030.
  • The Increasing of prevalence of chronic diseases is driving the intravenous solution

Know More About Global Intravenous (IV) Solution Report?

Have a Query? Click Here

Other Related Reports

Arnica Montana Comprehensive Study by Type (Arnica Ointment, Arnica Orally), Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Sales Channel (Direct, E-commerce), Source Type ...
$ 3350
Veterinary Electrosurgery Comprehensive Study by Type (Monopolar Electrosurgery, Bipolar Electrosurgery, Consumables & Accessories), Application (General Surgery, Ophthalmic Surgery, Orthopedic Surge...
$ 3650
Continence Care Comprehensive Study by Type (Urinary Continence Care, Fecal Continence Care), Application (Spinal Cord Injury, Benign Prostate Hyperplasia, Others), Product Type (Intermittent Cathete...
$ 3650
Topical Steroids Comprehensive Study by Application (Hospitals, Dermatology Clinics, Pharmacies), By Treatment (Dermatitis, Insect stings, Eczema, Psoriasis, Others), By Potency Class (Low, Moderate,...
$ 3450
Anaplastic Thyroid Cancer Treatment Comprehensive Study by Application (Hospital, Drugs Store, Others), Treatments (Surgical Treatments, Radiation Therapy, Novel Therapy, Others), Methods (Oral, Inje...
$ 3800
Women Healthcare Comprehensive Study by Type (Pregnancy, Menopause, Female Organ, Contraception, Osteoporosis, Fertility, Others), Application (Hospitals, Obstetrics & Gynecology Clinics, Diagnostic ...
$ 3750